As previously reported, Oppenheimer analyst Kevin DeGeeter initiated VBL Therapeutics with an Outperform rating and $2 price target. The analyst cited expectation for positive interim analysis from VB-111 Phase III OVAL study in platinum-resistant ovarian cancer around the end of 2019, potential for PFS analysis in 2020 to initiate discussions with FDA regarding accelerated approval of VB-111, and call option of market expansion of VB-111 in combination with checkpoint inhibitors and potentially for GBM as a monotherapy. Additionally, he expects the company to continue exploring opportunities to monetize its early stage pipeline.